InternationalUSRemember you can easily switch between MIP US and MIP International at any time

FDA adopts European approach to biosimilars

Eileen McDermott, New York

The Food and Drug Administration has shed some light on its approach to assessing biosimilars in a recent article published in the New England Journal of Medicine

The agency said it will take a so-called totality of the evidence approach to making regulatory decisions on biologic drugs. This approach was influenced in part by the European Medicines Agency (EMA), which approved its first biologic drug in 2006.

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null

null null null

November / December 2019

IP law: are the pressures taking their toll?

Following World Mental Health Day, Max Walters seeks the views of in-house professionals on whether they struggle with workplace pressures, and asks how to improve wellbeing

Most read articles